comprehensive -WSS

comprehensive

author：hotspot 2025-09-30 23:20:38 - browse：64193

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Alnylam reports growth in sales of rare disease treatments

leisure time

WSS

3 questions for the future of Biden's cancer moonshot

Heart disease in astronauts blamed on cosmic radiation

2 officers injured in shooting in Orlando, police say

Late stage cancers on the rise after pandemic delayed screenings

Why Charlie Gard's case is so disturbing to Americans

Chris Christie meets with Zelenskyy during Ukraine trip

Wikipedia

comprehensive

Wikipedia

The high cost of giving birth even with insurance

Sana to lay off nearly a third of staff, de

What does generative AI mean for health care? We asked experts

H.R. 3 is the wrong path to lower drug costs

Psychedelics group wrestles with new pharma identity

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Sana to lay off nearly a third of staff, de

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare slashes safety net hospital payments by nearly $1 billion

knowledge

Why age limits for politicians are a terrible idea

Colorectal cancer study finds potential in overlooked immune cell

Analysis of telehealth claims data suggest service duplication

FDA rejects Alnylam's heart disease treatment over insufficient data

VC firm General Catalyst wants to buy a health system

Bill would stop addiction treatment from triggering child abuse inquiry

leisure time

leisure time

focus

Wikipedia